William Dooley to Neoadjuvant Therapy
This is a "connection" page, showing publications William Dooley has written about Neoadjuvant Therapy.
Connection Strength
0.205
-
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precis Oncol. 2022 04; 6:e2100463.
Score: 0.189
-
Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer. Anticancer Res. 2006 Nov-Dec; 26(6C):4911-6.
Score: 0.016